SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-005839
Filing Date
2020-01-13
Accepted
2020-01-13 06:31:09
Documents
12
Period of Report
2020-01-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K d869721d8k.htm   iXBRL 8-K 23498
  Complete submission text file 0001193125-20-005839.txt   144638

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20200113.xsd EX-101.SCH 3052
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20200113_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20200113_pre.xml EX-101.PRE 11396
13 EXTRACTED XBRL INSTANCE DOCUMENT d869721d8k_htm.xml XML 3337
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 20522688
SIC: 2834 Pharmaceutical Preparations